MA39175A1 - Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives - Google Patents

Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives

Info

Publication number
MA39175A1
MA39175A1 MA39175A MA39175A MA39175A1 MA 39175 A1 MA39175 A1 MA 39175A1 MA 39175 A MA39175 A MA 39175A MA 39175 A MA39175 A MA 39175A MA 39175 A1 MA39175 A1 MA 39175A1
Authority
MA
Morocco
Prior art keywords
piperazin
phenylamino
pyrimidin
dimethoxy
dichloro
Prior art date
Application number
MA39175A
Other languages
English (en)
Inventor
Suzie Ribeiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39175A1 publication Critical patent/MA39175A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des formes pharmaceutiques solides comprenant la substance médicamenteuse 3- (2,6-dichloro -3,5-diméthoxy-phényl) -1- {6- [4- (4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin -4-yl} -1-méthyl-urée ou n'importe quel sel pharmaceutiquement acceptable de celle-ci. L'invention porte en outre sur des procédés de fabrication desdites formes pharmaceutiques solides.
MA39175A 2013-12-13 2014-12-11 Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives MA39175A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (fr) 2013-12-13 2014-12-11 Formes pharmaceutiques

Publications (1)

Publication Number Publication Date
MA39175A1 true MA39175A1 (fr) 2017-10-31

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39175A MA39175A1 (fr) 2013-12-13 2014-12-11 Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives

Country Status (33)

Country Link
US (3) US10278969B2 (fr)
EP (2) EP3597179B1 (fr)
JP (2) JP6522619B2 (fr)
KR (1) KR102349893B1 (fr)
CN (2) CN105813635A (fr)
AR (1) AR098716A1 (fr)
AU (1) AU2014362999B2 (fr)
CA (1) CA2930055C (fr)
CL (1) CL2016001436A1 (fr)
CY (1) CY1122063T1 (fr)
DK (1) DK3079667T3 (fr)
EA (1) EA036288B1 (fr)
EC (1) ECSP16060194A (fr)
ES (1) ES2745983T3 (fr)
HR (1) HRP20191691T1 (fr)
HU (1) HUE045156T2 (fr)
IL (1) IL245705B (fr)
LT (1) LT3079667T (fr)
MA (1) MA39175A1 (fr)
MX (1) MX2016007652A (fr)
MY (1) MY194303A (fr)
NZ (2) NZ719865A (fr)
PE (1) PE20160851A1 (fr)
PH (1) PH12016501039B1 (fr)
PL (1) PL3079667T3 (fr)
PT (1) PT3079667T (fr)
RS (1) RS59270B1 (fr)
SG (1) SG10202104627UA (fr)
SI (1) SI3079667T1 (fr)
TN (1) TN2016000207A1 (fr)
TW (2) TWI800759B (fr)
WO (1) WO2015087283A1 (fr)
ZA (1) ZA201603064B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105813635A (zh) 2013-12-13 2016-07-27 诺华股份有限公司 药物剂型
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2019046167A1 (fr) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. Formulations de pimavansérine
US20240009193A1 (en) * 2020-12-18 2024-01-11 Qed Therapeutics, Inc. Methods of treating achondroplasia
AU2022236428A1 (en) * 2021-03-17 2023-11-02 Laboratoires Juvise Pharmaceuticals Pharmaceutical dosage system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007071752A2 (fr) 2005-12-21 2007-06-28 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
RU2014103250A (ru) 2011-07-01 2015-08-10 Новартис Аг Комбинированная терапия
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CN105813635A (zh) 2013-12-13 2016-07-27 诺华股份有限公司 药物剂型
WO2016040882A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Polythérapie par les inhibiteurs de l'egfr
CN107787226A (zh) 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases

Also Published As

Publication number Publication date
PL3079667T3 (pl) 2020-02-28
NZ719865A (en) 2022-07-29
CN116942629A (zh) 2023-10-27
SI3079667T1 (sl) 2019-10-30
PT3079667T (pt) 2019-10-10
US10278969B2 (en) 2019-05-07
CA2930055A1 (fr) 2015-06-18
HUE045156T2 (hu) 2019-12-30
TWI721938B (zh) 2021-03-21
AU2014362999B2 (en) 2017-10-12
TN2016000207A1 (en) 2017-10-06
AR098716A1 (es) 2016-06-08
TW202128137A (zh) 2021-08-01
IL245705A0 (en) 2016-07-31
DK3079667T3 (da) 2019-09-09
EP3597179B1 (fr) 2024-04-03
CN105813635A (zh) 2016-07-27
EP3597179A1 (fr) 2020-01-22
LT3079667T (lt) 2019-09-10
SG10202104627UA (en) 2021-06-29
EP3079667A1 (fr) 2016-10-19
KR102349893B1 (ko) 2022-01-10
US11160804B2 (en) 2021-11-02
AU2014362999A1 (en) 2016-05-26
JP6522619B2 (ja) 2019-05-29
JP2017502941A (ja) 2017-01-26
ECSP16060194A (es) 2019-07-31
EA036288B1 (ru) 2020-10-22
US20220265651A1 (en) 2022-08-25
ZA201603064B (en) 2017-07-26
CA2930055C (fr) 2023-07-04
PH12016501039B1 (en) 2024-01-19
EP3079667B1 (fr) 2019-06-26
HRP20191691T1 (hr) 2019-12-27
ES2745983T3 (es) 2020-03-04
IL245705B (en) 2021-05-31
US20170007602A1 (en) 2017-01-12
NZ760002A (en) 2022-07-29
HK1223833A1 (en) 2017-08-11
MX2016007652A (es) 2016-10-13
RS59270B1 (sr) 2019-10-31
TW201605494A (zh) 2016-02-16
CY1122063T1 (el) 2020-11-25
JP2019142927A (ja) 2019-08-29
EA201691231A1 (ru) 2016-10-31
MY194303A (en) 2022-11-27
PH12016501039A1 (en) 2016-07-04
JP6804585B2 (ja) 2020-12-23
CL2016001436A1 (es) 2017-02-10
PE20160851A1 (es) 2016-09-14
US20200054632A1 (en) 2020-02-20
TWI800759B (zh) 2023-05-01
KR20160096093A (ko) 2016-08-12
WO2015087283A1 (fr) 2015-06-18

Similar Documents

Publication Publication Date Title
EA201100032A1 (ru) Соединения пиридина
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
BRPI0610187B8 (pt) tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA44759B1 (fr) Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide
MX2016013033A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados.
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
WO2014081712A3 (fr) Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton
MA39294B1 (fr) Polythérapie contre le cancer
CY1122063T1 (el) Φαρμακοτεχνικες δοσολογικες μορφες
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
PH12016500119A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical